Novo Nordisk’s Stock Went On A Crash Diet, And Investors Demonstrated Their Love For Oura
- Author
- Finimize
- Published
- Sat 21 Dec 2024
- Episode Link
- None
Novo Nordisk’s shares slimmed way down as investors felt disappointed by its latest obesity drug trial, while Oura raised $200 million from investors – proving it’s not just celebrities and executives who adore the Finnish smart rings.
Today’s stories:
